A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs.
Authors: Harman Robert, Carlson Kim, Gaynor Jamie, Gustafson Scott, Dhupa Sarit, Clement Keith, Hoelzler Michael, McCarthy Tim, Schwartz Pamela, Adams Cheryl
Journal: Frontiers in veterinary science
Summary
Osteoarthritis remains a significant welfare concern in dogs, and whilst mesenchymal stem cells (MSCs) have shown promise across veterinary species, rigorous efficacy data remain limited; this randomised, blinded, placebo-controlled trial evaluated whether intraarticular allogeneic adipose-derived stem cells could improve outcomes in 74 osteoarthritic dogs, assessing pain, function and owner-perceived improvement over 60 days post-injection. Dogs receiving a single dose of stem cells (either unilaterally or bilaterally) demonstrated substantially better outcomes than placebo controls across all measured parameters: owner-reported functional improvement reached 79.2% versus 55.4% in the placebo group (p=0.029), whilst objective veterinary assessment of pain on joint manipulation improved to 92.8% compared to 50.2% in placebo animals (p=0.017), and global clinical scoring similarly favoured treated dogs at 86.9% versus 30.8% (p=0.009). Notably, the treatment safety profile was excellent, with no significant difference in adverse events between groups, suggesting allogeneic stem cell therapy offers a viable option for managing canine osteoarthritis without unexpected complications. For equine professionals, this well-designed translational study provides valuable evidence supporting MSC efficacy and safety in a large animal model comparable to horses, informing emerging applications of regenerative medicine in performance and geriatric equine populations where osteoarthritis similarly limits function and quality of life.
Read the full abstract on PubMed
Practical Takeaways
- •Intraarticular allogeneic adipose stem cells demonstrate clinical efficacy for canine osteoarthritis with measurable improvements in pain and function within 60 days
- •The safety profile appears equivalent to placebo, making this a viable treatment option to discuss with clients managing dogs with OA
- •While this study is in dogs, the mechanistic similarities to equine OA suggest potential applicability, though species-specific efficacy studies would be needed
Key Findings
- •Intraarticular allogeneic adipose-derived MSCs significantly improved Client-Specific Outcome Measurement (CSOM) in treated dogs compared to placebo (79.2% vs 55.4%, p=0.029)
- •Veterinary pain on manipulation scores improved significantly in treated dogs versus placebo (92.8% vs 50.2%, p=0.017)
- •Veterinary global scores were significantly better in treated dogs compared to placebo (86.9% vs 30.8%, p=0.009)
- •No significant differences in adverse events or negative health findings were detected between treated and placebo groups